<?xml version='1.0' encoding='utf-8'?>
<document id="21426490"><sentence text="A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia."><entity charOffset="55-66" id="DDI-PubMed.21426490.s1.e0" text="simvastatin" /><entity charOffset="105-116" id="DDI-PubMed.21426490.s1.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.21426490.s1.e0" e2="DDI-PubMed.21426490.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21426490.s1.e0" e2="DDI-PubMed.21426490.s1.e1" /></sentence><sentence text="Simvastatin (SV), a HMG-CoA reductase inhibitor, is widely used for the treatment of hyperlipidaemia"><entity charOffset="0-11" id="DDI-PubMed.21426490.s2.e0" text="Simvastatin" /><entity charOffset="13-15" id="DDI-PubMed.21426490.s2.e1" text="SV" /><pair ddi="false" e1="DDI-PubMed.21426490.s2.e0" e2="DDI-PubMed.21426490.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21426490.s2.e0" e2="DDI-PubMed.21426490.s2.e1" /></sentence><sentence text=" The objectives of the present study were to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model for simvastatin and to evaluate its usefulness in predicting the dose-response relationship of simvastatin in patients with hyperlipidaemia"><entity charOffset="116-127" id="DDI-PubMed.21426490.s3.e0" text="simvastatin" /><entity charOffset="207-218" id="DDI-PubMed.21426490.s3.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.21426490.s3.e0" e2="DDI-PubMed.21426490.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21426490.s3.e0" e2="DDI-PubMed.21426490.s3.e1" /></sentence><sentence text=" The data were obtained from a drug-drug interaction study to assess the effect of aspirin on the PK of simvastatin"><entity charOffset="83-90" id="DDI-PubMed.21426490.s4.e0" text="aspirin" /><entity charOffset="104-115" id="DDI-PubMed.21426490.s4.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.21426490.s4.e0" e2="DDI-PubMed.21426490.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21426490.s4.e0" e2="DDI-PubMed.21426490.s4.e1" /></sentence><sentence text=" Twenty-seven healthy volunteers were given simvastatin 40 mg daily for 14 days in whom aspirin 100 mg q"><entity charOffset="44-55" id="DDI-PubMed.21426490.s5.e0" text="simvastatin" /><entity charOffset="88-95" id="DDI-PubMed.21426490.s5.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.21426490.s5.e0" e2="DDI-PubMed.21426490.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21426490.s5.e0" e2="DDI-PubMed.21426490.s5.e1" /></sentence><sentence text="d" /><sentence text=" was co-administered after day 8" /><sentence text=" Full PK studies were performed on days 1, 7 and 14 in addition to trough sampling on days 5, 6, 12 and 13" /><sentence text=" Low-density lipoprotein-cholesterol (LDL-C) levels were also measured serially"><entity charOffset="25-36" id="DDI-PubMed.21426490.s9.e0" text="cholesterol" /></sentence><sentence text=" Then, a population PK-PD model for simvastatin and its active metabolite, simvastatin acid (SVA), was developed using mixed effect methods (NONMEM Ver"><entity charOffset="36-47" id="DDI-PubMed.21426490.s10.e0" text="simvastatin" /><entity charOffset="75-91" id="DDI-PubMed.21426490.s10.e1" text="simvastatin acid" /><entity charOffset="93-96" id="DDI-PubMed.21426490.s10.e2" text="SVA" /><pair ddi="false" e1="DDI-PubMed.21426490.s10.e0" e2="DDI-PubMed.21426490.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21426490.s10.e0" e2="DDI-PubMed.21426490.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21426490.s10.e0" e2="DDI-PubMed.21426490.s10.e2" /><pair ddi="false" e1="DDI-PubMed.21426490.s10.e1" e2="DDI-PubMed.21426490.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21426490.s10.e1" e2="DDI-PubMed.21426490.s10.e2" /></sentence><sentence text=" 6" /><sentence text="2)" /><sentence text=" A simple linear PK model with parent and metabolite compartments provided the best fit for the 2647 concentrations of simvastatin and simvastatin acid, and a turnover model was used to describe the change in LDL-C levels"><entity charOffset="119-130" id="DDI-PubMed.21426490.s13.e0" text="simvastatin" /><entity charOffset="135-151" id="DDI-PubMed.21426490.s13.e1" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.21426490.s13.e0" e2="DDI-PubMed.21426490.s13.e0" /><pair ddi="false" e1="DDI-PubMed.21426490.s13.e0" e2="DDI-PubMed.21426490.s13.e1" /></sentence><sentence text=" The dose-response curve simulated from the final model and those obtained from the literature overlapped very closely" /><sentence text=" No influence of aspirin was observed in PK or PD"><entity charOffset="17-24" id="DDI-PubMed.21426490.s15.e0" text="aspirin" /></sentence><sentence text=" A simple PK-PD model developed using only 2-week study data from fewer than 30 healthy volunteers successfully predicted the dose-response relationship of simvastatin in patients when compared with published data"><entity charOffset="156-167" id="DDI-PubMed.21426490.s16.e0" text="simvastatin" /></sentence><sentence text="" /></document>